Laura Sepp-Lorenzino

CIK: 0001777421

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)1 (20.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

TSHA

Taysha Gene Therapies, Inc.

Director

LXEO

Lexeo Therapeutics, Inc.

Director

NTLA

Intellia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

TSHA
Taysha Gene Therapies, Inc.
Jun 1, 2026
Award(A)
Direct
21.3K shares-
LXEO
Lexeo Therapeutics, Inc.
Apr 28, 2026
Award(A)
Stock Option (right to buy)
Direct
50K shares-
TSHA
Taysha Gene Therapies, Inc.
Jun 2, 2025
Award(A)
Direct
56.6K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
9K shares at avg. $12.18$109K
NTLA
Intellia Therapeutics, Inc.
Jan 1, 2025
Exercise(M)
Direct
3.5K shares-

		Type	Shares	Price		Ownership
Jun 1, 2026	TSHA Taysha Gene Therapies, Inc.	Award(A)	21,335	-	$0	Direct
Apr 28, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A) Stock Option (right to buy)	50,000	-	-	Direct
Jun 2, 2025	TSHA Taysha Gene Therapies, Inc.	Award(A)	56,623	-	-	Direct
Jan 3, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	8,966	$12.18	$109,206	Direct
Jan 1, 2025	NTLA Intellia Therapeutics, Inc.	Exercise(M)	3,500	-	$0	Direct

1-5 of 5 transactions

About Sepp-Lorenzino Laura

Sepp-Lorenzino Laura (SEC CIK 0001777421) files insider reports with the SEC as Director of Taysha Gene Therapies, Inc. (TSHA), Director of Lexeo Therapeutics, Inc. (LXEO) and EVP, Chief Scientific Officer of Intellia Therapeutics, Inc. (NTLA).

Signal8 holds 5 ownership filings by Sepp-Lorenzino Laura, all Form 4s, filed between Jan 3, 2025 and Jun 2, 2026. Those filings report 5 transactions, from Jan 1, 2025 to Jun 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sepp-Lorenzino Laura's filings is in DALLAS, TX.

Recent filings by Sepp-Lorenzino Laura

Jun 1, 2026: Grant or award of TSHA shares (Form 4, code A).
Apr 28, 2026: Grant or award of LXEO derivative securities (Form 4, code A).
Jun 2, 2025: Grant or award of TSHA shares (Form 4, code A).
Jan 3, 2025: Open-market sale of NTLA shares (Form 4, code S).
Jan 1, 2025: Option exercise of NTLA shares (Form 4, code M).

Other insiders filing for Taysha Gene Therapies, Inc. (TSHA)

Nagendran Sukumar, President and Head of R&D
Stalfort John A III, Director
Donenberg Phillip B., Director
Long Alison S, Director
Alam Kamran, CHIEF FINANCIAL OFFICER
Nolan Sean P., Chief Executive Officer

How to read Form 4 transaction codes